Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies.
Thrombocytopenia was associated with the presence of heparin-coated pulmonary artery catheters in 12 patients with heparin-associated antiplatelet antibodies. The thrombocytopenia persisted so long as the heparin-coated catheters were in place, even when all other sources of heparin were discontinued. The high morbidity and mortality associated with heparin-induced thrombocytopenia mandates that heparin administration cease and that all heparin-coated catheters be removed from patients with heparin-associated antiplatelet antibodies.
Laster
J L
JL
Department of Surgery, University of Missouri-Columbia Health Sciences Center.
Nichols
W K
WK
Silver
D
D
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000276:immunology*; D001792:Blood Platelets / Q000276:immunology*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005260:Female; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011651:Pulmonary Artery; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D000906:Antibodies; D006493:Heparin